RenovoRx Company Insiders
RNXT Stock | USD 1.27 0.01 0.79% |
RenovoRx's insiders are aggressively buying. The analysis of the overall insider sentiment regarding RenovoRx suggests that vertually all insiders are extremely bullish. RenovoRx employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive.
RenovoRx's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2023-10-03 | Angela Nelms | Acquired 1100 @ 1.05 | View | ||
2022-06-07 | Ramtin Agah | Acquired 5182 @ 1.93 | View | ||
2022-05-19 | Shaun Bagai | Acquired 5500 @ 2.05 | View |
Monitoring RenovoRx's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
RenovoRx |
RenovoRx Management Team Effectiveness
The company has return on total asset (ROA) of (0.7008) % which means that it has lost $0.7008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5512) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.58 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.63). At this time, RenovoRx's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 4.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.4 M in 2024.Common Stock Shares Outstanding is likely to drop to about 10 M in 2024. Net Loss is likely to drop to about (9.3 M) in 2024
RenovoRx Workforce Comparison
RenovoRx is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 266. RenovoRx holds roughly 8.0 in number of employees claiming about 3% of equities under Health Care industry.
RenovoRx Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RenovoRx insiders, such as employees or executives, is commonly permitted as long as it does not rely on RenovoRx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, RenovoRx insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ryan Una S six days ago Acquisition by Ryan Una S of 11154 shares of RenovoRx at 5.91 subject to Rule 16b-3 | ||
Shaun Bagai over a week ago Acquisition by Shaun Bagai of 40983 shares of RenovoRx at 1.22 subject to Rule 16b-3 | ||
Spiegel Robert J. over two months ago Acquisition by Spiegel Robert J. of 25099 shares of RenovoRx at 1.02 subject to Rule 16b-3 | ||
Najmabadi Kamran over three months ago Disposition of 60000 shares by Najmabadi Kamran of RenovoRx at 0.5 subject to Rule 16b-3 | ||
Agah Ramtin over three months ago Acquisition by Agah Ramtin of 28424 shares of RenovoRx at 1.08 subject to Rule 16b-3 | ||
Agah Ramtin over six months ago Acquisition by Agah Ramtin of 52203 shares of RenovoRx at 6.04 subject to Rule 16b-3 | ||
Ryan Una S over six months ago Acquisition by Ryan Una S of 4582 shares of RenovoRx subject to Rule 16b-3 | ||
Leesa Gentry over six months ago Acquisition by Leesa Gentry of 190000 shares of RenovoRx at 1.69 subject to Rule 16b-3 |
RenovoRx Notable Stakeholders
A RenovoRx stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as RenovoRx often face trade-offs trying to please all of them. RenovoRx's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting RenovoRx's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Shaun Bagai | Secretary CEO | Profile | |
CGMA CPA | Controller VP | Profile | |
Ronald CPA | VP Controller | Profile | |
James Ahlers | Chief Officer | Profile | |
Leesa Gentry | Senior Operations | Profile | |
Angela Nelms | Chief Officer | Profile | |
Ryan Witt | Senior Partnerships | Profile | |
Ramtin MD | Chairman Founder | Profile |
About RenovoRx Management Performance
The success or failure of an entity such as RenovoRx often depends on how effective the management is. RenovoRx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of RenovoRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the RenovoRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (6.98) | (6.63) | |
Return On Capital Employed | (39.16) | (37.20) | |
Return On Assets | (6.98) | (6.63) | |
Return On Equity | 3.41 | 3.58 |
Please note, the imprecision that can be found in RenovoRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RenovoRx. Check RenovoRx's Beneish M Score to see the likelihood of RenovoRx's management manipulating its earnings.
RenovoRx Workforce Analysis
Traditionally, organizations such as RenovoRx use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare RenovoRx within its industry.RenovoRx Manpower Efficiency
Return on RenovoRx Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.3M | |
Net Loss Per Executive | 1.3M | |
Working Capital Per Employee | 36.4K | |
Working Capital Per Executive | 36.4K |
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.